Expression of peroxisome proliferator-activated receptor γ, E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases

Chinese Medical Journal

Volumn 120, Issue 17, 2007, Pages 1498-1504

  He, Qing ^a   Chen, Jie ^a   Lin, Han Liang ^a   Hu, Pin Jin ^a   Chen, Min Hu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

E cadherin; Gastric carcinoma; Matrix metalloproteinases 2; Metastases; Peroxisome proliferator activated receptor

Indexed keywords

GELATINASE A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UVOMORULIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CELL MEMBRANE; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DOWN REGULATION; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; STOMACH CARCINOGENESIS; STOMACH CARCINOMA; STOMACH MUCOSA; UPREGULATION;

EID: 34848859859     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200709010-00007     Document Type: Article

References (41)

1. Pisani P, Parkin DM, Bray F, Ferly J. Erratum: estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 870-873.
2. Liotta LA, Kohn E. Cancer invasion and metastases. JAMA 1990; 263: 1123-1126.
3. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncol 2004; 5: 419-429.
4. Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression. Ann N Y Acad Sci 2004; 1014: 155-163.
5. Kyrlagkitsis I, Karamanolis DG. Genes and gastric cancer. Hepatogastroenterology 2004; 51: 320-327.
6. Stetler-Stevenson WG, Yu AE. Proteinases in invasion: matrix metalloproteinases. Semin Cancer Biol 2001; 11: 143-152.
7. DeClerck YA, Yean TD, Chan D, Shimada H, Langley KE. Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res 1991; 51: 2151-2157.
8. Tanaka M, Kitajima Y, Edakuni G, Sato S, Miyazaki K. Abnormal expression of E-cadherin and beta-catenin may be a molecular marker of submucosal invasion and lymph node metastasis in early gastric cancer. Br J Surg 2002; 89: 236-244.
9. Chen J, Rocken C, Hoffmann J, Kruger S, Lendeckel U, Rocco A, et al. Expression of carbonic anhydrase 9 at the invasion front of gastric cancers. Gut 2005; 54: 920-927.
10. Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, et al. Expression of peroxisome proliferator-activated receptor (PPAR) γ in gastric cancer and inhibitory effects of PPAR γ agonists. Br J Cancer 2000; 83: 1394-1400.
11. Nomura S, Nakajima A, Ishimine S, Matsuhashi N, Kadowaki T, Kaminishi M. Differential expression of peroxisome proliferator-activated receptor in histologically different human gastric cancer tissues. J Exp Clin Cancer Res 2006; 25: 443-448.
12. Aldred MA, Morrison C, Gimin O, Hoang-Vu C, Krause U, Dralle H, et al. Peroxisome proliferator-activated receptor γ is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas. Oncogene 2003; 22: 3412-3416.
13. Jung TI, Baek WK, Suh SI, Jang BC, Song DK, Bae JH, et al. Down-regulation of peroxisome proliferator-activated receptor γ in human cervical carcinoma. Gynecol Oncol 2005; 97: 365-373.
14. Terashita Y, Sasaki H, Haruki N, Nishiwaki T, Ishiguro H, Shibata Y, et al. Decreased peroxisome proliferator-activated receptor γ gene expression is correlated with poor prognosis in patients with esophageal cancer. Jpn J Clin Oncol 2002; 32: 238-243.
15. Sasaki H, Tanahashi M, Yukiue H, Moiriyama S, Kobayashi Y, Nakashima Y, et al. Decreased perioxisome proliferator-activated receptor γ gene expression was correlated with poor prognosis in patients with lung cancer. Lung Cancer 2002; 36: 71-76.
16. Badawi AF, Badr MZ. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-γ and levels of prostaglandin E [2] and 15-deoxy-Δ[12,14]-prostaglandin J[2] in human breast cancer and metastasis. Int J Cancer 2003; 103:84-90.
17. Hase T, Yoshimura R, Mitsuhashi M, Segawa Y, Kawahito Y, Wada S, et al. Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists. Urology 2002; 60: 542-547.
18. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, et al. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58: 3344-3352.
19. Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y. Activation of PPAR γ inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999; 455: 135-139.
20. Theocharis S, Kanelli H, Politi E, Margeli A, Karkandaris C, Philippides T, et al. Expression of peroxisome proliferator activated receptor γ in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer 2002; 36: 249-255.
21. Han SW, Greene ME, Pitts J, Wada RK, Sidell N. Novel expression and function of peroxisome proliferator-activated receptor γ (PPARγ) in human neuroblastoma cells. Clin Cancer Res 2001; 7: 98-104.
22. Jiang WG, Redfern A, Bryce RP, Mansel RE. Peroxisome proliferator activated receptor-γ (PPAR-γ) mediates the action of γ linolenic acid in breast cancer cells. Prostaglandins Leukot Essent Fatty Acids 2000; 62: 119-127.
23. Katagiri Y, Takeda K, Yu ZX. Modulation of retinoid signalling through NGF-induced nuclear export of NGFI-B. Nat Cell Biol 2000; 2: 435-440.
24. Ikezoe T, Miller CW, Kawano S, Heaney A, Williamson EA, Hisatake J, et al. Mutational analysis of the peroxisome proliferator-activated receptor γ gene in human malignancies. Cancer Res 2001; 61: 5307-5310.
25. Ramesh S, Nash J, McCulloch PG. Reduction in membranous expression of beta-catenin and increased cytoplasmic E-cadherin expression predict poor survival in gastric cancer. Br J Cancer 1999; 81: 1392-1397.
26. Ohno T, Aihara R, Kamiyama Y, Mochiki E, Asao T, Kuwano H. Prognostic-significance of combined expression of MUC1 and adhesion molecules in advanced gastric cancer. Eur J Cancer 2006; 42: 256-263.
27. Zheng Z, Pan J, Chu B, Wong YC, Cheung AL, Tsao SW. Downregulation and abnormal expression of E-cadherin and beta-catenin in nasopharyngeal carcinoma: close association with advanced disease stage and lymph node metastasis. Hum Pathol 1999; 30: 458-466.
28. Hirohashi S, Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci 2003; 94: 575-581.
29. Miyaki M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Konishi M, Takeichi M. Increased cell-substratum adhesion, and decreased gelatinase secretion and cell growth, induced by E-cadherin transfection of human colon carcinoma cells. Oncogene 1995; 11: 2547-2552.
30. Koyama S. Enhanced cell surface expression of matrix metalloproteinases and their inhibitors, and tumor-induced host response in progression of human gastric carcinoma. Dig Dis Sci 2004; 49: 1621-1630.
31. Monig SP, Baldus SE, Hennecken JK, Spiecker DB, Spiecker DB, Grass G, et al. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2001; 39: 597-602.
32. Kabashima. A, Maehara Y, Kakeji Y, Baba H, Koga T, et al. Clinical pathological features and overexpression of matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis. Clin Cancer Res 2000; 6: 3581-3584.
33. Mori M, Mimori K, Yoshikawa Y, Shibata K, Utsunomiya T, Sadanaga N, et al. Analysis of the gene-expression profile regarding the progression of human gastric carcinoma. Surgery 2002; 131: S39-S47.
34. Rhee JS, Coussens LM. RECKing MMP function: implications for cancer development. Trends Cell Biol 2002; 12: 209-211.
35. Liu J, Lu H, Huang R, Lin D, Wu X, Lin Q, et al. Peroxisome proliferator activated receptor-γ ligands induced cell growth inhibition and its influence on matrix metallo-proteinase activity in human myeloid leukemia cells. Cancer Chemother Pharmacol 2005; 56: 400-408.
36. Ferruzzi P, Ceni E, Tarocchi M, Grappone C, Milani S, Galli A, et al. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab 2005; 90: 1332-1339.
37. Galli A, Ceni E, Crabb DW, Mello T, Salzano R, Grappone C, et al. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARγ independent mechanisms. Gut 2004; 53: 1688-1697.
38. Sasaki T, Fujii K, Yoshida K, Shimura H, Sasahira T, Ohmori H, et al. Peritoneal metastasis inhibition by linoleic acid with activation of PPARγ in human gastrointestinal cancer cells. Virchows Arch 2006; 448: 422-427.
39. Annicotte JS, Iankova I, Miard S, Fritz V, Sarruf D, Abella A, et al. Peroxisome proliferator-activated receptor γ regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 2006; 26: 7561-7574.
40. Bocca C, Bozzo F, Francica S, Colombatto S, Miglietta A. Involvement of PPARγ and E-cadherin/beta-catenin pathway in the anti-proliferative effect of conjugated linoleic acid in MCF-7 cells. Int J Cancer 2007; 121: 248-256.
41. Ohta T, Elnemr A, Yamamoto M, Ninomiya I, Fushida S, Nishimura G, et al. Thiazolidinedione, a peroxisome proliferator-activated receptor γ ligand, modulates the E-cadherin/beta-catenin system in a human pancreatic cancer cell line, BxPC-3. Int J Oncol 2002; 21: 37-42.